AKR1B1 and AL amyloidosis: The aldo-keto reductase AKR1B1 is associated with diabetes mellitus and is broadly overexpressed in human cancers; AKR1B1 overexpression is related to shortened patient survival in acute myelogenous leukemia and multiple myelomas [38].